1) Buying rubbish divestment's that are over priced and hard to integrate and being hammered with future regulations on cost - the latter should have been considered in the risk thesis. 2) Developing a manufacturing plant that is making next to nothing in terms of a percentage of total revenues - why? what is the plan to make this more revenue generating ? 3) Not a solid plan to increase investor returns other than saying we will - how ? 4) Diluting everyone with never ending option bonuses 5) reduction in some share holder value of greater than 70% 6) Slow market updates and regulatory approval updates - time lines people.
Solutions * Move into real R&D and investing in a pipeline of product development trials - increase share-holder wealth this way - 3-4 solid diversified products could add 100 million for each one. Hint university shopping for early stage discoveries with good science behind it. * Pivot to look at Herbal - at least something that will not hold back regulatory development and cost regulation * Vet market place tap this. * Partnerships with small cap pharma where cash and equity in other companies can accumulate for manufacturing solutions and possible distribution rights. Reverse of what they have been doing - giving away equity and increasing debt.
What would help * Board shake-up * Activist investor to turn this around
MYX Price at posting:
45.0¢ Sentiment: Sell Disclosure: Held
(20min delay)